drugset / Trial / NCT04007991

Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents

NCT04007991

Phase 2 Completed 153 enrolled Emalex Biosciences Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study evaluates the effect of ecopipam tablets in children and adolescents in the treatment of Tourette's Syndrome (TS). Half of the participants will receive ecopipam tablets, while the other half will receive matching placebo tablets

Timeline

Start
2019-06-28
Primary completion
2021-09-23
Completion
2021-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Ecopipam Small molecule 2 mg/kg Oral

Indications